secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001193125-23-202349
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics Q2 2023 net loss $9.4M; SNS-101 Phase 1/2 enrolling 6 patients
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $78.8M at June 30, 2023, down from $107.1M at Dec 31, 2022; cash runway into H2 2025.
- Net loss $9.4M vs $10.5M YoY; R&D expenses $4.8M (down from $6.4M) due to restructuring and lower manufacturing costs.
- G&A expenses $5.4M included $1.56M non-recurring stockholder activism costs related to the 2023 annual meeting.
- SNS-101 Phase 1/2 enrolled 6 patients across 3 cohorts; combination arm with Libtayo (cemiplimab) expected Q4 2023; PK/safety data by year-end 2023.
- Robert Schreiber appointed Chair of Immuno-Oncology Advisory Board; SNS-102 and SNS-103 lead optimization completed, candidate selection expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523202349/0001193125-23-202349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523202349/d518119d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-202349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer